Study: Effect of Mastic supplementation on NAFLD: The MAST4HEALTH Randomised, Controlled Trial

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease with poor therapeutic strategies. Mastic gum possesses antioxidant/anti-inflammatory and lipid-lowering properties. The authors investigate the effectiveness of Mastic as a nonpharmacological intervention in NAFLD.

Methods and Results

Ninety-eight patients with NAFLD in three countries (Greece, Italy, Serbia) are randomly allocated to either Mastic or Placebo for 6 months, as part of a multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial. The authors assess NAFLD severity via magnetic resonance imaging (MRI) scanning and LiverMultiScan technique and evaluate the effectiveness of Mastic through medical, anthropometric, biochemical, metabolomic, and microbiota assessment.

Mastic is not superior to Placebo on changes in iron-corrected T1 (cT1) and Liver Inflammation Fibrosis score (LIF) in entire patient population; however, after BMI stratification (BMI ≤ 35 kg m-2 and BMI > 35 kg m-2), severely obese patients show an improvement in cT1 and LIF in Mastic versus Placebo. Mastic increases dissimilarity of gut microbiota, as shown by the Bray-Curtis index, downregulates Flavonifractor, a known inflammatory taxon and decreases Lysophosphatidylcholines-(LysoPC) 18:1, Lysophosphatidylethanolamines-(LysoPE) 18:1, and cholic acid compared to Placebo.

Conclusion

Mastic supplementation improves microbiota dysbiosis and lipid metabolite levels in patients with NAFLD, although it reduces parameters of liver inflammation/fibrosis only in severely obese patients.

You can find the whole study here.

Study: Effect of Mastic supplementation on NAFLD: The MAST4HEALTH Randomised, Controlled Trial

Chios Mastic in NAFLD – Clinical Study Summary

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder, with limited treatment options. Chios Mastic gum, due to its antioxidant, anti-inflammatory, and lipid-lowering properties, was tested as a nonpharmacological intervention.

  • Study design: Multicenter, randomized, double-blind, placebo-controlled trial in 98 patients across Greece, Italy, and Serbia. Participants received either Mastic or Placebo for 6 months.
  • Assessments: Liver severity via MRI and LiverMultiScan, along with medical, biochemical, metabolomic, and microbiota analyses.
  • Findings: Overall, Mastic did not outperform Placebo in liver inflammation/fibrosis scores (cT1, LIF) in the full cohort.
  • Severely obese patients (BMI > 35 kg/m²) showed improvement in liver parameters with Mastic compared to Placebo.
  • Mastic supplementation improved gut microbiota diversity, downregulated the inflammatory taxon Flavonifractor, and decreased certain lipid metabolites (LysoPC 18:1, LysoPE 18:1, cholic acid).

Conclusion: Mastic helps restore microbiota balance and improves lipid metabolism, with liver inflammation/fibrosis benefits observed mainly in severely obese NAFLD patients.

Full study here.

Mastic for your gastrointestinal tract

View all